Outcome
    Moderate Evidence

    Urolithin A for Cellular Health

    Urolithin A has unusually good mechanistic human data for a novel longevity ingredient.

    Overview

    Urolithin A is unusual among longevity compounds in having real human trial data - and equally unusual in how modest the demonstrated effects are.
    It is a gut bacterial metabolite of ellagitannins found in pomegranate, walnuts and berries, and randomised placebo-controlled trials in older adults have shown improved muscle endurance, favourable shifts in mitochondrial gene expression and plasma acylcarnitines, and reduced inflammatory markers at 500-1000 mg daily. A trial in middle-aged adults reported improved muscle strength and aerobic endurance. Only around 40 percent of people carry the gut bacteria needed to produce urolithin A from dietary precursors, which is the strongest argument for direct supplementation. What has not been shown is any effect on ageing, lifespan or disease outcomes - the trials measure muscle and mitochondrial biomarkers.

    No studies are currently linked to this pairing

    This page reflects published clinical literature and conventional dosing rather than trial data attached to this outcome in our library.

    How It Works

    Mitophagy is the selective removal of damaged mitochondria, and it declines with age, allowing dysfunctional organelles to accumulate and generate reactive oxygen species while producing less ATP. This accumulation is a recognised hallmark of cellular ageing.
    Urolithin A induces mitophagy, apparently through PINK1 and parkin-dependent pathways, clearing damaged mitochondria and stimulating biogenesis of new ones. In animal models this improves muscle function and extends lifespan in nematodes; in human trials it shifts mitochondrial gene expression and acylcarnitine profiles in the expected direction. Production from food depends entirely on gut microbiota composition. Non-producers gain nothing from eating pomegranate for this purpose, which is why the isolated compound exists as a product at all.

    Dosing & Protocol

    Trial doses are well defined and consistent across the small literature.
    ContextDoseFormTiming
    Standard trial dose500 mg dailySynthetic urolithin A (e.g. Mitopure)Morning with food
    Higher studied dose1000 mg dailySynthetic urolithin AWith food
    Dietary precursor routePomegranate, walnuts, berriesWhole food ellagitanninsOnly effective in the ~40% who are producers
    Assessment window8-16 weeks-Trials ran 4 months; endurance and biomarker changes were gradual

    Resistance training beats it comfortably

    Exercise induces mitophagy and mitochondrial biogenesis far more powerfully than any supplement, and has decades of outcome data behind it.

    Evidence

    There are currently no studies linked to this pairing in our library, so no study list is shown.
    Randomised placebo-controlled trials in older and middle-aged adults report improved muscle endurance and strength, favourable mitochondrial gene expression and acylcarnitine changes, and reduced inflammatory markers, with a good safety profile at 500-1000 mg daily over four months. For a compound in this category, that is an unusually respectable evidence base. The qualifications are considerable: few trials, modest sample sizes, primarily biomarker and performance endpoints rather than clinical outcomes, durations of no more than four months, and substantial manufacturer involvement in the key studies. Nothing demonstrates effects on ageing, disease risk or longevity in humans.

    Real trials, biomarker endpoints

    Genuine randomised human data on muscle endurance and mitochondrial markers. No evidence for slowed ageing or disease prevention.

    Safety

    Urolithin A was well tolerated in trials at up to 1000 mg daily for four months, with adverse event rates similar to placebo and no clinically meaningful changes in liver, kidney or haematological parameters. It has been granted GRAS status in the United States.

    Long-term safety is genuinely unknown

    The longest trials ran four months. A compound that alters mitochondrial turnover taken for years has no safety data behind it.

    Safety in pregnancy, breastfeeding and children has not been studied, and there is no data in significant liver or kidney disease. Unexplained fatigue, muscle weakness or exercise intolerance can indicate thyroid disease, anaemia, heart failure or a mitochondrial disorder, and warrants investigation rather than supplementation.

    Interactions & Conflicts

    Few pharmacological interactions are known; the main issues are conceptual and evidentiary.
    Interacts withSeverityMechanismAction
    Resistance and endurance training
    low
    		Both stimulate mitochondrial biogenesis; exercise is far strongerTrain first; treat this as an add-on
    High-dose antioxidant supplements
    low
    		May blunt exercise-induced mitochondrial adaptationAvoid megadoses around training
    Antibiotics
    low
    		Disrupt the microbiota that produce urolithin A from foodRelevant only for the dietary precursor route
    Pregnancy and breastfeeding
    moderate
    		No safety dataAvoid
    Cost versus benefit
    low
    		Expensive relative to demonstrated effect sizeWeigh against exercise and protein intake first

    References

    No studies are currently linked to this pairing, so no reference list is available. This section will populate as evidence is added to the library.

    Frequently Asked Questions

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.